Skip to main content

Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

Endocrine volume 54, pages 603–611 (2016)Cite this article

Abstract

Glucocorticoid-induced osteoporosis is the most frequent form of secondary osteoporosis caused by chronic exposure to glucocorticoid excess. Pathogenesis of glucocorticoid-induced osteoporosis is multifactorial including direct effects of glucocorticoids on bone cells and indirect effects of glucocorticoids on several neuroendocrine and metabolic pathways. Fragility fractures occur early in glucocorticoid-induced osteoporosis and anti-osteoporotic drugs along with calcium and vitamin D should be started soon after exposure to glucocorticoid excess. This paper summarizes some of the main topics discussed during the 9th Glucocorticoid-Induced Osteoporosis Meeting (Rome, April 2016) with a specific focus on the role of growth hormone/insulin-like growth factor-1 and parathyroid hormone/vitamin D axes in the pathogenesis of glucocorticoid-induced osteoporosis and the controversial aspects concerning therapeutic approach to skeletal fragility in this clinical setting.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007)

    CAS  Article  PubMed  Google Scholar 

  2. A. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: summary of a workshop. J. Clin. Endocrinol. Metab. 86, 5681–5685 (2001)

    CAS  Article  PubMed  Google Scholar 

  3. T. Mancini, M. Doga, G. Mazziotti, A. Giustina, Cushing’s syndrome and bone. Pituitary 7, 1–4 (2005)

    Article  Google Scholar 

  4. G. Mazziotti G, A. Delgado, F. Maffezzoni, A. Formenti, A. Giustina, Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66–73 (2016)

    Article  PubMed  Google Scholar 

  5. P. Vestergaard, J. Lindholm, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, L.O. Kristensen, U. Feldt-Rasmussen, L. Mosekilde, Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur. J. Endocrinol. 146, 51–56 (2002)

    CAS  Article  PubMed  Google Scholar 

  6. A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao; ABC group, treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos. Int. 25, 441–446 (2015)

    Article  CAS  Google Scholar 

  7. G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)

    CAS  Article  PubMed  Google Scholar 

  8. N.E. Lane, W. Yao, M. Balooch, R.K. Nalla, G. Balooch, S. Habelitz, J.H. Kinney, L.F. Bonewald, Glucocorticoid treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466–476 (2006)

    CAS  Article  PubMed  Google Scholar 

  9. T.P. Van Staa, R.F. Laan, I.P. Barton, S. Cohen, D.M. Reid DM, C. Cooper, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224–3229 (2003)

    Article  CAS  PubMed  Google Scholar 

  10. G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol 9, 265–276 (2013)

    CAS  Article  PubMed  Google Scholar 

  11. C.E. Dean, B. Morpurgo, T.E. Porter, Induction of somatotroph differentiation in vivo by corticosterone administration during chicken embryonic development. Endocrine 11, 151–156 (1999)

    CAS  Article  PubMed  Google Scholar 

  12. A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717–797 (1998)

    CAS  PubMed  Google Scholar 

  13. A. Tamaki, M. Sato, S. Matsubara, Y. Wada, J. Takahara, Dexamethasone increases growth hormone (GH)-releasing hormone (GHR) receptor mRNA levels in culture rat anterior pituitary cells. Neuroendocrinology 8, 475–480 (1996)

    CAS  Article  Google Scholar 

  14. A. Giustina, G. Romanelli, R. Candrina, G. Giustina, Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J. Clin. Endocrinol. Metab. 68, 120–124 (1989)

    CAS  Article  PubMed  Google Scholar 

  15. Y. Hattori, T. Takeda, M. Fujii, J. Taura, Y. Ishii, H. Yamada, Dioxin-induced fetal growth retardation: the role of a preceding attenuation in the circulating level of glucocorticoid. Endocrine 47, 572–580 (2014)

    CAS  Article  PubMed  Google Scholar 

  16. A. Giustina, G. Mazziotti, Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. Endocrine 47, 354–356 (2014)

    CAS  Article  PubMed  Google Scholar 

  17. W.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127, 2705–2708 (1990)

    CAS  Article  PubMed  Google Scholar 

  18. G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, A. Giustina, Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218–1224 (2002)

    CAS  Article  PubMed  Google Scholar 

  19. A. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg, Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J. Clin. Endocrinol. Metab. 74, 1301–1305 (1992)

    CAS  PubMed  Google Scholar 

  20. A. Giustina, M. Doga, C. Bodini, A. Girelli, F. Legati, S. Bossoni, G. Romanelli, Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. Acta Endocrinol. 122, 206–210 (1990)

    CAS  PubMed  Google Scholar 

  21. M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina, C. Tantucci, Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127, 515–521 (2005)

    CAS  Article  PubMed  Google Scholar 

  22. M. Terzolo, S. Bossoni, A. Alı, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, A. Giustina, Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J. Clin. Endocrinol. Metab. 85, 1310–1315 (2000)

    CAS  Article  PubMed  Google Scholar 

  23. Z. Hochberg, Mechanisms of steroid impairment of growth. Horm. Res. 58, S33–S38 (2002)

    Google Scholar 

  24. H. Filipsson, G. Johannsson, GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur. J. Endocrinol. 161, S85–S95 (2009)

    CAS  Article  PubMed  Google Scholar 

  25. A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, R. Giorgino, L. Moro, A. Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253–259 (2006)

    CAS  Article  PubMed  Google Scholar 

  27. G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)

    CAS  Article  PubMed  Google Scholar 

  28. A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80, 122–129 (1995)

    CAS  PubMed  Google Scholar 

  29. F.F. Horber, M.W. Haymond, Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J. Clin. Invest. 86, 265–272 (1990)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. M.A. Magiakou, G.P. Chrousos GP, Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J. Endocrinol. Invest. 25, 181–194 (2002)

    CAS  Article  PubMed  Google Scholar 

  31. R.G. McArthur, M.D. Cloutier, A.B. Hayles, R.G. Sprague, Cushing’s disease in children. Findings in 13 cases. Mayo. Clin. Proc. 47, 318–326 (1972)

    CAS  PubMed  Google Scholar 

  32. D.H. Streeten, F.H. Faas, M.J. Elders, T.G. Dalakos, M. Voorhess, Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 56, 797–803 (1975)

    CAS  PubMed  Google Scholar 

  33. C.G. Thomas Jr., A.T. Smith, J.M. Griffith, F.B. Askin, Hyperadrenalism in childhood and adolescence. Ann. Surg. 199, 538–548 (1984)

    Article  PubMed  PubMed Central  Google Scholar 

  34. M.A. Magiakou, G. Mastorakos, G.P. Chrousos, Final stature in patients with endogenous Cushing’s syndrome. J. Clin. Endocrinol. Metab. 79, 1082–1085 (1994)

    CAS  PubMed  Google Scholar 

  35. N.R. Hughes, C.A. Lissett, S.M. Shalet, Growth hormone status following treatment for Cushing’s syndrome. Clin. Endocrinol. (Oxf). 51, 61–66 (1999)

    CAS  Article  PubMed  Google Scholar 

  36. M.A. Magiakou, G. Mastorakos, M.T. Gomez, S.R. Rose, G.P. Chrousos, Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J. Clin. Endocrinol. Metab. 78, 131–137 (1994)

    CAS  PubMed  Google Scholar 

  37. M.O. Savage, A. Lienhardt, M.C. Lebrethon, L.B. Johnston, A. Huebner, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, Cushing’s disease in childhood: presentation, investigation, treatment and long-term outcome. Horm. Res. 55(Suppl 1), 24–30 (2001)

    CAS  PubMed  Google Scholar 

  38. M.C. Lebrethon, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, M.O. Savage, Linear growth and final height after treatment for Cushing’s disease in childhood. J. Clin. Endocrinol. Metab. 85, 3262–3265 (2000)

    CAS  PubMed  Google Scholar 

  39. L.F. Chan, H.L. Storr, P.N. Plowman, L.A. Perry, G.M. Besser, A.B. Grossman, M.O. Savage, Long-term anterior pituitary function in patients with paediatric Cushing’s disease treated with pituitary radiotherapy. Eur. J. Endocrinol. 156, 477–482 (2007)

    CAS  Article  PubMed  Google Scholar 

  40. V. Khanine, J.J. Fournier, E. Requeda, J.P. Luton, F. Simon, J. Crouzet, Osteoporotic fractures at presentation of Cushing’s disease: two case reports and a literature review. Joint Bone Spine 67, 341–345 (2000)

    CAS  PubMed  Google Scholar 

  41. L. Futo, J. Toke, A. Patocs, A. Szappanos, I. Varga, E. Glaz, Z. Tulassay, K. Racz, M. Toth, Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing’s syndrome. Osteoporos. Int. 19, 941–949 (2008)

    CAS  Article  PubMed  Google Scholar 

  42. K. Godang, T. Ueland, J. Bollerslev, Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing’s syndrome. Eur. J. Endocrinol. 141, 126–131 (1999)

    CAS  Article  PubMed  Google Scholar 

  43. A.R. Hermus, A.G. Smals, L.M. Swinkels, D.A. Huysmans, G.F. Pieters, C.F. Sweep, F.H. Corstens, P.W. Kloppenborg PW, Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 80, 2859–2865 (1995)

    CAS  PubMed  Google Scholar 

  44. A. Kawamata, M. Iihara, T. Okamoto, T. Obara, Bone mineral density before and after surgical cure of Cushing’s syndrome due to adrenocortical adenoma: prospective study. World J. Surg. 32, 890–896 (2008)

    Article  PubMed  Google Scholar 

  45. A.W. van der Eerden, M. den Heijer, W.J. Oyen, A.R. Hermus, Cushing’s syndrome and bone mineral density: lowest Z scores in young patients. Neth. J. Med. 65, 137–141 (2007)

    PubMed  Google Scholar 

  46. C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, P. Marzullo, A. Di Sarno, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood-onset disease. Clin. Endocrinol. 56, 153–158 (2002)

    Article  Google Scholar 

  47. D.J. Devoe, W.L. Miller, F.A. Conte, S.L. Kaplan, M.M. Grumbach, S.M. Rosenthal, C.B. Wilson, S.E. Gitelman, Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing’s disease. J. Clin. Endocrinol. Metab. 82, 3196–3202 (1997)

    CAS  PubMed  Google Scholar 

  48. C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin. Endocrinol. 58, 302–308 (2003)

    Article  Google Scholar 

  49. I. Jeong, M. Oh, J.H. Kim, J.H. Cho, J.H. Choi, H.W. Yoo, Long-term follow-up on Cushing disease patient after transsphenoidal surgery. Ann. Pediatr. Endocrinol. Metab. 19, 164–168 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  50. S. Scommegna, J.P. Greening, H.L. Storr, K.M. Davies, N.J. Shaw, J.P. Monson, A.B. Grossman, M.O. Savage, Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease. J. Endocrinol. Invest. 28, 231–235 (2005)

    CAS  Article  PubMed  Google Scholar 

  51. G.M. Leong, L.B. Mercado-Asis, J.C. Reynolds, S.C. Hill, E.H. Oldfield, G.P. Chrousos, : The effect of Cushing’s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J. Clin. Endocrinol. Metab. 81, 1905–1911 (1996)

    CAS  PubMed  Google Scholar 

  52. G.M. Leong, V. Abad, E. Charmandari, J.C. Reynolds, S. Hill, G.P. Chrousos, L.K. Nieman, Effects of child- and adolescent-onset endogenous cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J. Bone Miner. Res. 22, 110–118 (2007)

    Article  PubMed  Google Scholar 

  53. M.B. Lodish, H.P. Hsiao, A. Serbis, N. Sinaii, A. Rothenbuhler, M.F. Keil, S.A. Boikos, J.C. Reynolds, C.A. Stratakis, Effects of Cushing disease on bone mineral density in a pediatric population. J. Pediatr. 156, 1001–1005 (2010)

    Article  PubMed  PubMed Central  Google Scholar 

  54. Y. Zhang, D.Y.M. Leung, E. Goleva, Vitamin D enhances glucocorticoid action in human monocytes. J. Biol. Chem. 288, 14544–14553 (2013)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  55. S.M. Tse, H.W. Kelly, A.A. Litonjua, M.L. Van Natta, S.T. Weiss, K.G. Tantisira; Childhood Asthma Management Program Research Group, Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J. Allergy Clin. Immunol. 130, 53–60 (2012)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. Z.E. Davidson, K.Z. Walker, H. Truby, Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J. Clin. Endocrinol. Metab. 97, 738–744 (2012)

    CAS  Article  PubMed  Google Scholar 

  57. E. Romagnoli, J. Pepe, S. Piemonte, C. Cipriani, S. Minisola, Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur. J. Endocrinol. 169, R59–R69 (2013)

    CAS  Article  PubMed  Google Scholar 

  58. C. Cipriani, J. Pepe, S. Piemonte, L. Colangelo, M. Cilli, S. Minisola, Vitamin d and its relationship with obesity and muscle. Int. J. Endocrinol. 2014, 841248 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. S. Huybers, T.H. Naber, R.J. Bindels, J.G. Hoenderop, Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G92–G97 (2007)

    CAS  Article  PubMed  Google Scholar 

  60. J. Pepe, E. Romagnoli, I. Nofroni, M.T. Pacitti, S. De Geronimo, C. Letizia, G.,G. Tonnarini, A. Scarpiello, E. D’Erasmo, S. Minisola, Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos. Int. 16, 805–812 (2005)

    CAS  Article  PubMed  Google Scholar 

  61. E. Paz-Pacheco, G. El-Hajj Fuleihan, M. Leboff, Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J. Bone Miner. Res. 10, 1713–1718 (1995)

    CAS  Article  PubMed  Google Scholar 

  62. S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. Agabiti-Rosei, D. Valle, N. Iori, J.P. Bilezikian, J.D. Veldhuis, A. Giustina, Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152, 199–205 (2005)

    CAS  Article  PubMed  Google Scholar 

  63. K.E. Hansen, H.A. Wilson, C. Zapalowski, H.A. Fink, S. Minisola, R.A. Adler, Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 26, 1989–96 (2011)

    Article  PubMed  Google Scholar 

  64. J.M. Grossman, R. Gordon, V.K. Ranganath, C. Deal, L. Caplan, W. Chen, J.R. Curtis, D.E. Furst, M. McMahon, N.M. Patkar, E. Volkmann, K.G. Saag, American college of rheumatology recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res. 62, 1515–1526 (2010)

    Article  Google Scholar 

  65. S. Lekamwasam, J.D. Adachi, D. Agnusdei, J.P. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L.C. Hofbauer, J.A. Kanis, B.L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O.D. Messina, N. Napoli, B. Obermayer-Pietsch, S.H. Ralston, P.N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D.A. Wahl, J.E. Compston; Joint IOF-ECTS GIO Guidelines Working Group, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis Int. 23, 2257–2276 (2012)

    CAS  Article  Google Scholar 

  66. A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53–58 (2011)

    CAS  Article  PubMed  Google Scholar 

  67. R.P. Heaney, M.F. Holick, Why the IOM recommendations for vitamin D are deficient. J. Bone Miner. Res. 26, 455–457 (2011)

    CAS  Article  PubMed  Google Scholar 

  68. K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U.A. Liberman, P.D. Delmas, M.P. Malice, M. Czachur, A.G. Daifotis, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced osteoporosis intervention study group. N. Engl. J. Med. 339, 292–299 (1998)

    CAS  Article  PubMed  Google Scholar 

  69. J.D. Adachi, K.G. Saag, P.D. Delmas, U.A. Liberman, R.D. Emkey, E. Seeman, N.E. Lane, J.M. Kaufman, P.E. Poubelle, F. Hawkins, R. Correa-Rotter, C.J. Menkes, J.A. Rodriguez-Portales, T.J. Schnitzer, J.A. Block, J. Wing, H.H. McIlwain, R. Westhovens, J. Brown, J.A. Melo-Gomes, B.L. Gruber, M.J. Yanover, M.O. Leite, K.G. Siminoski, M.C. Nevitt, J.T. Sharp, M.P. Malice, T. Dumortier, M. Czachur, W. Carofano, A. Daifotis, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202–211 (2001)

    CAS  Article  PubMed  Google Scholar 

  70. S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, S.M. Doherty, M. Maricic, C. Rosen, J. Brown, I. Barton, A.A. Chines, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277–285 (2000)

    CAS  Article  PubMed  Google Scholar 

  71. D.M. Reid, J.P. Devogelaer, K.G. Saag, C. Roux, C.S. Lau, J.Y. Reginster, P. Papanastasiou, A. Ferreira, F. Hartl, T. Fashola, P. Mesenbrink, P.N. Sambrook; HORIZON investigators, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253–1263 (2009)

    CAS  Article  PubMed  Google Scholar 

  72. T. Petranova, I. Sheytanov, S. Monov, R. Nestorova, R. Rashkov, Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol. Biotechnol. Equip. 28, 1127–1137 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. C.C. Mok, L.Y. Ho, K.M. Ma, Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75, 222–228 (2015)

    CAS  Article  PubMed  Google Scholar 

  74. T. Takeuchi, Y. Tanaka, N. Ishiguro, H. Yamanaka, T. Yoneda, T. Ohira, N. Okubo, H.K. Genant, D. van der Heijde, Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann. Rheum. Dis. 75, 983–990 (2016)

    Article  PubMed  Google Scholar 

  75. L. Gennari, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet 373, 1225–1226 (2009)

    Article  PubMed  Google Scholar 

  76. K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Eng. J. Med. 357, 2028–2039 (2007)

    CAS  Article  Google Scholar 

  77. K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346–3355 (2009)

    CAS  Article  PubMed  Google Scholar 

  78. J.P. Devogelaer, R.A. Adler, C. Recknor, K. See, M.R. Warner, M. Wong, K. Krohn, Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141–148 (2010)

    CAS  Article  PubMed  Google Scholar 

  79. B.L. Langdahl, F. Marin, E. Shane, H. Dobnig, J.R. Zanchetta, M. Maricic, K. Krohn, K. See, M.R. Warner, Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int. 12, 2095–2104 (2009)

    Article  CAS  Google Scholar 

  80. C.C. Glüer, F. Marin, J.D. Ringe, F. Hawkins, R. Möricke, N. Papaioannu, P. Farahmand, S. Minisola, G. Martínez, J.M. Nolla, C. Niedhart, N. Guañabens, R. Nuti, E. Martín-Mola, F. Thomasius, G. Kapetanos, J. Peña, C. Graeff, H. Petto, B. Sanz, A. Reisinger, P.K. Zysset, Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1355–1368 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. G. Mazziotti, F. Maffezzoni, M. Doga, L.C. Hofbauer, R.A. Adler, A. Giustina, Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. Bone 67, 175–180 (2014)

    CAS  Article  PubMed  Google Scholar 

  82. K. Briot, B. Cortet, C. Roux, L. Fardet, V. Abitbol, J. Bacchetta, D. Buchon, F. Debiais, P. Guggenbuhl, M. Laroche, E. Legrand, E. Lespessalilles, C. Marcelli, G. Weryha, T. Thomas, Bone section of the french society for rheumatology (SFR) and osteoporosis research and information group (GRIO). Joint Bone Spine 81, 493–501 (2014)

    Article  PubMed  Google Scholar 

  83. H.O. Tory, D.H. Solomon, S.P. Desai, Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis. Sem. Arthritis Rheum. 44, 483–488 (2015)

    CAS  Article  Google Scholar 

  84. A.H. Warriner, R.C. Outman, J.J. Allison, J.R. Curtis, N.J. Markward, D.T. Redden, M.M. Safford, E.J. Stanek, A.R. Steinkellner, K.G. Saag, An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users. J. Rheumatol. 42, 1478–1483 (2015)

    CAS  Article  PubMed  Google Scholar 

  85. J.R. Curtis, A.O. Westfall, J. Allison, Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch. Intern. Med. 167, 591–596 (2007)

    Article  PubMed  Google Scholar 

  86. D.H. Solomon, J.N. Katz, J.P. Jacobs, A.M. La Tourette, J. Coblyn, Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 51, 383–387 (2004)

    CAS  Article  PubMed  Google Scholar 

  87. M.J. Kohler, M. Amezaga, J. Drozd, S.T. Crowley, B. Gulanski, D.R. Anderson, L. Fraenkel, Use of a computerized order set to increase prescription of calcium and vitamin D supplementation in patients receiving glucocorticoids. J. Gen. Intern. Med. 28, 825–829 (2013)

    Article  PubMed  PubMed Central  Google Scholar 

  88. E.D. Newman, C.K. Matzko, T.P. Olenginski, J.L. Perruquet, T.M. Harrington, G. Maloney-Saxon, T. Culp, G.C. Wood, Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at1 year. Osteoporos. Int. 17, 1428–1434 (2006)

    CAS  Article  PubMed  Google Scholar 

Download references

Funding

This study was not funded by any grant

Author information

Affiliations

  1. Chair of Endocrinology, University of Brescia, Brescia, Italy

    Gherardo Mazziotti, Anna Maria Formenti & Andrea Giustina

  2. McGuire Veterans Affairs Medical Center, Virginia Commonwealth University School of Medicine Richmond, Virginia, USA

    Robert A. Adler

  3. Department of Medicine Columbia University College of Physicians and Surgeons, New York, NY, USA

    John P. Bilezikian

  4. Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, OX3 7LE, UK

    Ashley Grossman & Emilia Sbardella

  5. Department of Internal Medicine and Medical Disciplines “Sapienza” Rome University, Rome, Italy

    Salvatore Minisola

Authors
  1. Gherardo Mazziotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Maria Formenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John P. Bilezikian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ashley Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emilia Sbardella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Salvatore Minisola
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrea Giustina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Giustina.

Ethics declarations

Conflict of interest

G.M. received lecture fee from Abiogen Pharma SpA, J.P.B. was consultant for Merck, Amgen, Radius and received Research Grant from Shire Pharmaceuticals, A.Gr. received lecture fees and Advisory Board payments from Novartis, Ipsen and HRA Pharma, S.M. received lecture fees from Abiogen Pharma SpA, Amgen, Diasorin, Eli Lilly, Italfarmaco, Fujii, Merck Sharp & Dohme, Takeda and Advisory Board payments from Amgen and Eli Lilly, A.Gi. was consultant for Abiogen Pharma SpA. A.M.F., R.A.A. and E.S. declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mazziotti, G., Formenti, A.M., Adler, R.A. et al. Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54, 603–611 (2016). https://doi.org/10.1007/s12020-016-1146-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-1146-8

Keywords

  • Glucocorticoids
  • Osteoporosis
  • Growth hormone
  • Vitamin D
  • PTH
  • Guidelines